MIAMI, Nov. 28, 2011 /PRNewswire/ -- Femina Pharma Incorporated announces the issuance of Order 24 in Investigation No. 337-TA-768 (In the matter of Certain Vaginal Ring Birth Control Devices) by the Administrative Law Judge at the United States International Trade Commission ("ITC") denying the Merck Respondents' Motion for Summary Determination on the basis of lack of Domestic Industry. The issuance of Order 24 follows the prior issuance on July 15, 2011 of Order 14 denying Merck's Motion for Summary Determination of Invalidity of U.S. Patent No. 6,086,909.
On February 11, 2011, Femina Pharma Incorporated filed a complaint with the ITC for infringement of the '909 patent through importation of certain vaginal ring birth control devices, including NuvaRing® against Merck & Co., Inc., Schering Plough Corporation, Organon USA, Inc., N.V. Organon, Wal-Mart Stores, Inc., CVS Pharmacy, Inc., Walgreen Co. and several Canadian On-Line Pharmacies. The Canadian On-Line Pharmacies have been held in default. NuvaRing® was acquired by Merck through its 2009 acquisition of Schering Plough.
Separately, Femina Pharma Incorporated announces the November 15, 2011 filing of a patent infringement lawsuit in federal district court in the Eastern District of Virginia against Merck & Co., Inc., Schering Plough Corporation, Organon USA, Inc., Wal-Mart Stores, Inc., CVS Pharmacy, Inc. and Walgreen Co. alleging infringement of the '909 patent by the NuvaRing® (C.A. no. 1:11cv1248) (the "District Action"). The District Action seeks monetary damages and injunctive relief.
Joseph Matus Fuisz, CEO of Femina Pharma, stated: "We are pleased with the Order denying the Merck Respondents' Motion for Summary Determination on the basis of lack of Domestic Industry. Femina continues to exploit the claimed technology and has every right to seek redress at the ITC to protect US industry from infringing foreign impo
|SOURCE Femina Pharma Incorporated|
Copyright©2010 PR Newswire.
All rights reserved